Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

261

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

December 30, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

9MW2921

All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.

Trial Locations (1)

Fudan University Shanghai Cancer Centel, Shanghai

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT05990452 - Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter